 Antisense modulation of telomeric repeat binding factor 1 expression |
| OF THE INVENTION The present invention employs oligomeric antisense compounds, particularly ... |
|
| Antisense modulation of interleukin-5 signal transduction |
| OF THE INVENTION The present invention comprehends antisense compounds capable of modulating IL-5 ... |
|
| Antisense modulation of P38 mitogen activated protein kinase expression |
| OF THE INVENTION p38 MAPKs play an important role in signal transduction in response to cytokines, ... |
|
| Antisense modulation of CD44 expression |
| OF THE INVENTION The present invention employs oligomeric antisense compounds, particularly ... |
|
| Antisense modulation of Smad7 expression |
| OF THE INVENTION The present invention employs oligomeric antisense compounds, particularly ... |
|
| Antisense modulation of nucleolin expression |
| OF THE INVENTION The present invention employs oligomeric antisense compounds, particularly ... |
|
| Antisense modulation of hnRNP A1 expression |
| OF THE INVENTION The present invention employs oligomeric antisense compounds, particularly ... |
|
| Antisense inhibition of E2F transcription factor 3 expression |
| OF THE INVENTION The present invention employs oligomeric antisense compounds, particularly ... |
|
| Antisense inhibition of rank expression |
| OF THE INVENTION The present invention employs oligomeric antisense compounds, particularly ... |
|
| Antisense inhibition of protein kinase C-theta expression |
| OF THE INVENTION The present invention employs oligomeric antisense compounds, particularly ... |
|
|
Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
| Details |
Inventors: Matulic-Adamic, Jasenka; Beigelman, Leonid; Karpeisky, Alexander; Jarvis, Thale; Usman, Nassim; DiRenzo, Anthony; Wincott, Francine;
Assignee: Ribozyme Pharmaceuticals, Inc. (Boulder, CO)
Primary Examiner: Degen; Nancy
Assistant Examiner: Larson; Thomas G.
Attorney, Agent or Firm: Lyon & Lyon LLP
An enzymatic nucleic acid molecule comprising a 5'- and/or a 3'-cap structure, wherein said structure is not a 5'-5'-linked inverted nucleotide or a 3'-3'-linked inverted nucleotide. |
|
DETAILED DESCRIPTION We claim: 1.
An enzymatic nucleic acid molecule comprising a 5'-cap structure, a 3'-cap structure, or both a 5'- and a 3'-cap structure, wherein said 5'-cap structure is selected from the group consisting of 4',5'-methylene nucleotide; 1-(.
beta.
-D-erythrofuranosyl)nucleotide; 4'-thio nucleotide, carbocyclic nucleotide; 5'-amino-alkyl phosphate; 1,3-diamino-2-propyl phosphate, 3-aminopropyl phosphate; 6-aminohexyl phosphate; 12-aminododecyl phosphate; hydroxypropyl phosphate; 1,5-anhydrohexitol nucleotide; L-nucleotide; alpha-nucleotide; threo-pentofuranosyl nucleotide; acyclic 3',4'-seco nucleotide; 3,4-dihydroxybutyl nucleotide; 3,5-dihydroxypentyl nucleotide, 5'-5'-inverted abasic moiety; 1,4-butanediol phosphate; 5'-amino; and bridging or non bridging methylphosphonate and 5'-mercapto moieties, and wherein said 3'-cap structure is selected from the group consisting of 4'-thio nucleoside, carbocyclic nucleotide; 1,5-anhydrohexitol nucleotide; L-nucleotide; alpha-nucleotide; modified base nucleotide; threo-pentofuranosyl nucleotide; acyclic 3',4'-seco nucleotide; 3,4-dihydroxybutyl nucleotide; 3,5-dihydroxypentyl nucleotide; 3'-3'-inverted abasic moiety; 3'-2'-inverted nucleotide moiety; 3'-2'-inverted abasic moiety; 1,4-butanediol; hexylphosphate; aminohexyl phosphate; 3'-phosphate; and a bridging methylphosphonate moiety.
2.
The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule is in a hammerhead motif.
3.
The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule is in a hairpin, hepatitis delta virus, group I intron, VS RNA or RNase P RNA motif.
4.
The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule comprises said 5'-cap structure.
5.
The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule comprises said 3'-cap structure.
6.
The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule comprises said 5'-cap structure and said 3'-cap structure
|
| Related patents |
|
|
Peptide acceptor ligation methods
What is claimed is: 1. A method of affixing a peptide acceptor to an RNA molecule, said method comprising: (a) providing an RNA molecule having a 3' sequence which forms ...
|
|
|
Solid phase diagnosis of medical conditions
I claim: 1. A method for detecting a target polynucleotide that is characteristic of a pathological condition, comprising the steps of: (a) producing a first amplified DN...
|
|
|
Use of microparticles combined with submicron oil-in-water emulsions
OF THE INVENTION The practice of the present invention will employ, unless otherwise indicated, conventional methods of chemistry, biochemistry, molecular biology, ...
|
|
|
Methods of treating hypertension and compositions for use therein
The present invention provides methods of treating hypertension, particularly essential hypertension. The methods generally involve providing a stimulator of ...
|
|
|
Use of microparticles combined with submicron oil-in-water emulsions
OF THE INVENTION The practice of the present invention will employ, unless otherwise indicated, conventional methods of chemistry, biochemistry, molecular biology, ...
|
|
|
6,11-bicyclic erythromycin derivatives
OF THE INVENTION A first embodiment of the present invention is a compound of formula I as defined herein, or its pharmaceutically acceptable salt, ester, or prodrug. R...
|
|
|
Method of producing infectious reovirus
OF THE INVENTION The present invention is directed to a method of producing mammalian reovirus by using human embryo kidney 293 (HEK 293) cells. We found that HEK 293 ...
|
|
|
CDNA sequences of human bone matrix proteins
It is, therefore, an object of the present invention to provide specific cDNA and deduced protein sequences which are diagnostic of such human diseases as osteoporosis, ...
|
|
|
Antisense inhibition of PEPCK-mitochondrial expression
OF THE INVENTION The present invention employs oligomeric antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid ...
|
|
|
Methods of modulating tumor necrosis factor .alpha.-induced expression of cell adhesion molecules
OF THE INVENTION The present invention employs specific inhibitors of Ha-ras, c-raf and JNK2, members of the TNF-.alpha. signaling pathway, to modulate cell adhesion ...
|
|
|
Gene Therapy 
